The role of interim 18F-FDG PET/CT in predicting early response to neoadjuvant chemotherapy in breast cancer.

Kisoo Pahk, Seunghong Rhee, Jaehyuk Cho, Minhee Seo, Sinae Lee, Taegyu Park, Soyeon Park, Eunsub Lee, Kyong Hwa Park, Chulhan Kim, Jae Seon Eo, Sungeun Kim, Jae-Gol Choe

Research output: Contribution to journalArticlepeer-review

13 Citations (Scopus)


The aim of this study was to prove the diagnostic value of interim 18F-Fluorodeoxyglucose-positron-emission tomography combined with computed tomography (PET/CT) scan for predicting pathological complete response (pCR) compared to other factors in neoadjuvant chemotherapy. Twenty-seven patients with breast cancer were included in this retrospective study. They all underwent scheduled neoadjuvant chemotherapy. Patients underwent PET/CT at baseline, mid-point (interim), and preoperatively (after completion of chemotherapy). The metabolic response was calculated as follows: ΔStandardized uptake value (SUV)(%)=(1st SUV(max)-2nd SUV(max))/1st SUV(max) × 100. The change in SUVmax between baseline and interim PET/CT scans was significantly larger than between interim and preoperative PET/CT scan. An optimal cut-off ΔSUV value of 78.3% was proposed for discriminating patients with pCR from those without pCR. Metabolic CR, defined as a change of SUV(max) greater than the cut-off value, can predict pCR according to univariate analysis (p=0.012; Relative risk (RR)=25.3). Furthermore, metabolic CR was the most powerful factor for predicting pCR than other possible factors according to multivariate analysis (p=0.003). It is possible to use interim (18)F-FDG PET-CT as an effective method to predict early response in patients with breast cancer treated with neoadjuvant chemotherapy. Copyright

Original languageEnglish
Pages (from-to)4447-4455
Number of pages9
JournalAnticancer Research
Issue number8
Publication statusPublished - 2014 Jan 1

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'The role of interim 18F-FDG PET/CT in predicting early response to neoadjuvant chemotherapy in breast cancer.'. Together they form a unique fingerprint.

Cite this